凭借在微生物发酵领域60年的技术积累，鲁抗医药将这种优势延伸至生物农药领域，从植物源、微生物 源中发现天然活性成分，打造出生物杀虫剂、杀菌剂、植物生长调节剂等产品为农田生态保驾护航。在 土壤养护层面，鲁抗生物农药的功能菌剂有涵养墒情的功效，枯草芽孢杆菌制剂通过微生物竞争作用改 良土壤微生态，改善土壤板结问题，提升保水保肥能力，搭配赤霉素等植物生长调节剂，更能促进作物 根系发育，增强植株抗逆性，真正实现生物菌养根的双重增益。 "十五五"期间，鲁抗医药将扩增发酵类农药数量和规模，建成国内领先的生物农药企业，做好规划布 局，聚焦大单品，将农药制剂单品成本降至最低。将不断提升创新能力，加快创新农药的注册和投产， 使更多的生物农药科研成果从实验室走向田间地头，提供保障农作物安全生产和生态平衡的系统性方 案，积极打造绿色农业科技力量，为建设农业强国贡献鲁抗智慧！ 鲁抗医药生物农药依托生物间的相互作用或天然活性物质，用"顺应自然"的智慧化解农业难题，它不会 像化学农药那样在土壤中积累持久性污染物，而是能在完成防治任务后自然降解，回归自然，守护农田 里的生态平衡。这份"温柔的守护"，恰如中国传统文化中所蕴含的"敬畏自然、尊重 ...

每经头条（nbdtoutiao）——伤亡180万人！俄乌冲突四周年，陷入谈判死局、战场僵局、经济困局！谁 为战争买单 （记者 曾健辉） 每经AI快讯，鲁抗医药2月24日晚间发布公告称，近日，山东鲁抗医药股份有限公司控股子公司山东鲁 抗医药集团赛特有限责任公司收到国家药品监督管理局颁发的关于米诺地尔搽剂的《药品注册证书》， 该药品是按照新注册分类3类获批的仿制药，视为通过仿制药质量和疗效一致性评价。产品名称为"米诺 地尔搽剂"。 ...

财经频道更多独家策划、专家专栏，免费查阅>> 责任编辑：磐石 格隆汇2月24日丨鲁抗医药(600789.SH)公布，公司控股子公司山东鲁抗医药集团赛特有限责任公司（简 称"赛特公司"）收到国家药品监督管理局颁发的关于米诺地尔搽剂（简称"该药品"）的《药品注册证 书》（批件号：2026S00478、2026S00479），该药品是按照新注册分类3类获批的仿制药，视为通过仿 制药质量和疗效一致性评价。 米诺地尔属于钾通道开放类抗高血压药物但具有多毛症的副作用。美国Upjohn公司针对此种不良反应进 行研究发现其溶液外用治疗秃发有明显疗效。1988年9月经美国FDA批准2%米诺地尔外用溶液上市用于 治疗斑秃男性秃发及化疗后秃发，1991年FDA批准可在妇女中使用，1997年FDA批准上市了5%米诺地 尔外用溶液用于男性患者。目前国内有米诺地尔搽剂、米诺地尔酊等相关剂型用于治疗秃发。本品用于 治疗男性型脱发和斑秃。 ...

智通财经APP讯，鲁抗医药(600789.SH)发布公告，近日，公司控股子公司山东鲁抗医药集团赛特有限 责任公司(以下简称"赛特公司")收到国家药品监督管理局颁发的关于米诺地尔搽剂(以下简称"该药品") 的《药品注册证书》(批件号：2026S00478、2026S00479)，该药品是按照新注册分类3类获批的仿制 药，视为通过仿制药质量和疗效一致性评价。 ...

证券代码：600789 证券简称：鲁抗医药 公告编号：2026-008 山东鲁抗医药股份有限公司 关于控股子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，山东鲁抗医药股份有限公司（以下简称"公司"）控股子公司山东鲁 抗医药集团赛特有限责任公司（以下简称"赛特公司"）收到国家药品监督管理 局颁发的关于米诺地尔搽剂（以下简称"该药品"）的《药品注册证书》（批件 号：2026S00478、2026S00479），该药品是按照新注册分类 3 类获批的仿制药， 视为通过仿制药质量和疗效一致性评价。现将相关情况公告如下： 一、药品证书基本信息 药品名称： 米诺地尔搽剂 剂型： 搽剂 规格：5%（60 毫升：3.0 克）、2%（60 毫升：1.2 克） 原药品批准文号：国药准字 H20263408、国药准字 H20263407 药品注册标准编号：YBH35432025 注册分类：化学药品 3 类 生产企业：山东鲁抗医药集团赛特有限责任公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 ...

Overview - The company, Shandong Lukang Pharmaceutical Co., Ltd., has approved the government acquisition of part of its state-owned land use rights, involving a total area of 237,100 square meters (approximately 355.65 acres) [1] - The company will receive a total compensation of 360.396 million yuan for the land acquisition, which includes a specific compensation of 22.82256 million yuan for land previously owned by Shandong Lukang Pharmaceutical Group Co., Ltd. [1] Compensation Progress - The company has received a total of 152.277 million yuan in land compensation payments to date, with an outstanding balance of 208.119 million yuan yet to be received [2] - The compensation payments were received in multiple installments, including 20 million yuan on September 29, 2024, 32.277 million yuan on May 22, 2025, 50 million yuan on August 27, 2025, 20 million yuan on September 25, 2025, and 10 million yuan on December 30, 2025 [2] Future Actions - The company will closely monitor and follow up on the progress of the remaining land compensation payments and related matters, ensuring timely information disclosure to investors [3]

证券代码:600789 证券简称:鲁抗医药 公告编号:2026-007 山东鲁抗医药股份有限公司 （公告编号：2022-066）、《鲁抗医药关于公司南厂区土地办理完成移交手续 暨进展公告》（公告编号：2024-034）。 2024年9月29日，公司收到第一笔土地收储补偿款2,000万元；2025年5月22 日，公司收到第二笔土地补偿款3,227.70万元；2025年8月27日，公司收到第三 笔土地补偿款5,000万元；2025年9月25日，公司收到第四笔土地补偿款2,000万 元；2025年12月30日，公司收到第五笔土地补偿款1,000万元。具体内容详见公 司2024年9月30日、2025年5月23日、2025年8月28日、2025年9月26日、2025年 12月31日披露的《关于收到南厂区土地收储补偿款的进展公告》（公告编号： 2024-048、2025-025、2025-042、2025-049、2025-060）。 二、本次收储相关事项的进展情况 2026年2月13日，公司收到第六笔土地补偿款2,000万元。截至目前公司已 收到土地补偿款15,227.70万元，尚未收到补偿款余额20,811.90万元 ...

Group 1 - The company announced the acquisition of five state-owned construction land parcels totaling 237,100 square meters, with a total compensation fee of 360.396 million yuan [1] - As of February 13, 2026, the company received the sixth installment of land compensation amounting to 20 million yuan [1] - The total compensation received to date is 152.277 million yuan, with an outstanding balance of 208.119 million yuan yet to be received [1]

Core Viewpoint - The company has developed an action plan titled "Enhancing Quality, Increasing Efficiency, and Returning to Shareholders" to improve operational quality and governance in response to regulatory requirements and its own strategic goals [1][8]. Group 1: Business Focus and Quality Improvement - The company is a state-controlled comprehensive pharmaceutical enterprise engaged in the research, production, and sales of pharmaceutical and biological manufacturing products, with a mission to develop ecological medicine and serve human health [1]. - Future strategies include optimizing business structure and enhancing operational efficiency, focusing on product innovation and establishing a high-quality development system [2]. Group 2: Innovation and Product Line Expansion - The company adheres to an "innovation-driven development" strategy, maintaining R&D investment at over 6% of revenue during the 14th Five-Year Plan period, and has achieved breakthroughs in innovative drugs and biological manufacturing [2][3]. - The product structure is continuously optimized, with competitive advantages in anti-infection, diabetes, and cardiovascular drugs, and a growing pipeline of specialty products [2]. Group 3: Governance and Compliance - The company is committed to improving its governance structure in accordance with relevant laws and regulations, ensuring transparency and effective checks and balances [3][4]. - It has revised its articles of association and internal control systems to enhance operational standardization and compliance [3]. Group 4: Long-term Return Mechanism - The company emphasizes investor returns, with cash dividends exceeding 30% of net profit attributable to ordinary shareholders from 2021 to 2024, and has incorporated a cash dividend policy into its articles of association [5]. - The company aims to enhance its operational quality to increase investment value and fulfill its commitment to shareholder returns [5]. Group 5: Information Disclosure and Investor Relations - The company adheres to strict information disclosure regulations, focusing on transparency and the quality of disclosed information to ensure all shareholders receive timely updates [6]. - It plans to enhance investor relations management through diversified communication channels and actively seek investor feedback [6]. Group 6: Management of Key Personnel - The company prioritizes the responsibilities of key stakeholders, including controlling shareholders and senior management, to safeguard the interests of minority shareholders [7]. - It implements a multi-level governance system to ensure compliance and risk management, while enhancing the performance evaluation and incentive mechanisms for senior management [7].

Core Viewpoint - The company, LuKang Pharmaceutical, has announced a special action plan titled "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" aimed at enhancing operational quality and driving innovation in product development [1] Group 1: Action Plan Details - Focus on core business to improve operational quality [1] - Drive development through innovation and continuously enrich the product line [1] - Optimize corporate governance to enhance operational standards [1] - Establish a long-term return mechanism to share development results [1] - Improve the quality of information disclosure and strengthen investor relations management [1] - Strengthen management of key personnel to solidify responsibility [1] - Additional explanations provided [1]